Navigation Links
Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients

that results of clinical trials are not predictive of safety and efficacy results of Soliris in broader patient populations, the risk that third parties won't agree to license any necessary intellectual property to us on reasonable terms, the risk that third party payors will not reimburse for the use of Soliris at acceptable rates or at all, the risk that Soliris will not generate interest among physicians, the risk that estimates regarding the number of PNH patients are inaccurate, the risk that pending litigation may be resolved adversely, and a variety of other risks set forth from time to time in Alexion's filings with the Securities and Exchange Commission, including but not limited to the risks discussed in Alexion's Quarterly Report on Form 10-Q for the period ended March 31, 2007 and in our other filings with the Securities and Exchange Commission. Alexion does not intend to update any of these forward-looking statements to reflect events or circumstances after the date hereof, except when a duty arises under law.

1 Hillmen P. The Terminal Complement Inhibitor Eculizumab Reduces Thrombosis in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). Study accepted for presentation at the 12th Congress of European Hematology, organized by The European Hematology Association (EHA), on Saturday, June 9 in Vienna, Austria.

2 Schrezenmeier H. Safety and Efficacy of the Terminal Complement Inhibitor Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): SHEPHERD Phase III Clinical Study Results. Study accepted for presentation at the 12th Congress of European Hematology, organized by The European Hematology Association (EHA), on Saturday, June 9 in Vienna, Austria.

3 Muus P. The Clinical Benefit of Eculizumab is Demonstrable in All Subpopulations of Patients with Paroxysmal Nocturnal Hemoglobinuira PNH with Hemolysis. Study accepted for oral presentation at the 12th Congress of European Hematology, organized by The European Hem
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
2. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
3. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
4. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
5. Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of Blindness in Premature Infants
6. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
7. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
8. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
9. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
10. Eurands Zentase Effective in Treating Exocrine Pancreatic Insufficiency, Studies Show
11. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
Post Your Comments:
(Date:7/30/2015)... -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today ... the second quarter ending June 30, 2015. ... organization.  We are excited to be near the completion ... conducted with topline results expected in the fourth quarter," ... Therapeutics, Inc. "Translarna is now commercially available in 12 ...
(Date:7/30/2015)... WOODCLIFF LAKE, N.J. , July 30, 2015 /PRNewswire/ ... submitted simultaneously in the United States ... (to the FDA, EMA and MHLW, respectively) for eribulin, ... sarcoma (STS) who have received prior chemotherapy for advanced ... are based on data from a pivotal global Phase ...
(Date:7/30/2015)... FAIRFIELD, N.J. , July 30, 2015 /PRNewswire/ ... Ferrer, completed the second Phase III clinical study ... development for impetigo.  Medimetriks owns the exclusive U.S. ... The global trial, conducted at 44 centers with ... and pediatric patients aged 2 months and older ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
... 2012 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: ... received written notification on May 25, 2012, from the ... York Stock Exchange LLC ("NYSE"), that the staff had ... of the Company and file a delisting application with ...
... Today the House passed H.R. 5651, its version ... including important provisions to mitigate drug shortages, most notably ... the world,s largest professional society concerned with the causes ... members who specialize in blood cancers such as leukemia, ...
Cached Medicine Technology:American Oriental Bioengineering Inc. Announces Suspension of Trading in its Common Stock and the Initiation of Delisting Proceedings by NYSE 2American Society of Hematology Statement on House Passage of Prescription Drug User Fee Act (PDUFA) 2
(Date:7/30/2015)... California (PRWEB) , ... July 30, 2015 , ... ... services, announced today that the latest issue of Inclusive™ magazine, its multimedia publication ... platforms. The digital edition of the new issue, Volume 6, Issue 2, as ...
(Date:7/30/2015)... ... 2015 , ... Western University of Health Sciences faculty, students and alumni were ... largest sports and humanitarian event in the world this year and the single biggest ... July 25 through August 2, 2015, benefited from the participation of WesternU’s colleges of ...
(Date:7/30/2015)... ... July 30, 2015 , ... On July 23rd ... in taxpayer money to fund the state’s large prison system, which has amassed largely ... highest rates of incarceration. In light of President Obama’s recent reduction of non violent ...
(Date:7/30/2015)... ... July 30, 2015 , ... Quintessa Medical Spa is happy to offer ... treatment designed specifically for the elimination of excess tissue under the chin, referred ... the state of Wisconsin to offer this innovative treatment. , Developed by Kythera Biopharmaceuticals, ...
(Date:7/30/2015)... ... July 30, 2015 , ... Gummy smile surgeon, Dr. Alex ... and surgery, as well as the patented gum depigmentation treatmet. Dr. Farnoosh is a ... with many patients from around the world. , “Like treatment of any other disease ...
Breaking Medicine News(10 mins):Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 2Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 4Health News:WesternU Makes Big Impact at Special Olympics 2Health News:WesternU Makes Big Impact at Special Olympics 3Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 2Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 3Health News:Quintessa MedSpa Offers Nonsurgical Double-chin Elimination 2Health News:Gummy Smile Dentist, Alex Farnoosh DMD, is Now Offering Comprehensive Treatment Options for Gummy Smiles 2
... Center in Philadelphia have found that a signaling protein ... turned on in nearly all recurrent prostate cancers that ... up, the protein, called Stat5, may be a specific ... addition, the researchers, led by Marja Nevalainen, M.D., Ph.D., ...
... and use caution when exiting transportation , , SUNDAY, Dec. 30 ... slush and ice of winter requires special walking tactics, health ... careful, particularly since we haven,t had this type of weather ... specialist at Mount Sinai,s Department of Orthopaedics in New York ...
... injuries can happen to kids if precautions are skipped, ... Winter sports provide kids with great exercise and fun, ... say pediatric trauma experts. , "We see a startling ... snowmobile crashes and beyond," Amy Teddy, manager of the ...
... to make a different kind of New Year,s resolution, ... America,s Blood Centers and blood transfusion recipients across,the country ... National Blood Donor Month., Each year, more than ... to a recent study by W. Riley (et al) ...
... Dec. 28 Grubb & Ellis,Healthcare REIT, Inc. has ... closed on December 21, 2007., Park Place Office ... 133,000 square feet on eight and a half,acres in ... constructed in 1987,1988, and 2002, respectively, and offer tenants ...
... 500 Jobs, HARRISBURG, Pa., Dec. 28 A ... of the Butler,Memorial Hospital that will include a new ... the Department of Community and,Economic Development announced today. The ... The state,s aid will come in the form ...
Cached Medicine News:Health News:Jefferson scientists find protein potential drug target for treatment-resistant prostate cancer 2Health News:Put Safety First During Winter Fun 2Health News:America's Blood Centers Thanks Donors During Celebration of National Blood Donor Month 2Health News:America's Blood Centers Thanks Donors During Celebration of National Blood Donor Month 3Health News:Grubb & Ellis Healthcare REIT Acquires Park Place Office Park in Dayton, Ohio 2Health News:Grubb & Ellis Healthcare REIT Acquires Park Place Office Park in Dayton, Ohio 3Health News:Pennsylvania Invests $13.4 Million to Kick Off Butler Memorial Hospital Expansion 2
... opticians in a store environment. Optizone ... retail store industry by opticians. Optizone ... for Optizone 2000. It is written ... User friendly screen interfaces make learning ...
This product offers patient, product and practice cash management to ease the strain of practice administration....
... MaximEyes by First Insight is the ... records solution for eye care professionals. ... with Eyefinitys online servicesrequest VSP authorizations, ... MaximEyes offers EMR, scheduling, billing, demographics, ...
... software for eyecare professionals- Winx ... multi-office practice management system, using ... Winx Pro is a complete ... in effectively managing the administrative, ...
Medicine Products: